Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design
- 30 September 1999
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Cardiac Failure
- Vol. 5 (3), 276-282
- https://doi.org/10.1016/s1071-9164(99)90013-1
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Effect of Bradykinin-Receptor Blockade on the Response to Angiotensin-Converting–Enzyme Inhibitor in Normotensive and Hypertensive SubjectsNew England Journal of Medicine, 1998
- Alternative pathways of angiotensin II production in the human saphenous veinBritish Journal of Pharmacology, 1998
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- Angiotensin Receptors and Their AntagonistsNew England Journal of Medicine, 1996
- Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failureArchives of Internal Medicine, 1996
- Neurohumoral Mechanisms in Heart Failure: A Central Role for the Renin-Angiotensin SystemJournal of Cardiovascular Pharmacology, 1996
- Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspectiveJournal of the American College of Cardiology, 1995
- Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor TrialsJAMA, 1995